Abstract
Background: Headache (HA) is a very common neurological problem in the pediatric population. Topiramate (TPM) is currently approved in children 2years of age and older as an adjunctive treatment of partial and primary generalized seizures. Historically, anticonvulsants have proven effective for adult HA and, in fact, given this, and the availability of safety data on TPM in the pediatric population, it is an agent that holds promise for HA prophylaxis in children. There is at least one small case report indicating efficacy in pediatric migraine but there are /INS;no studies to date including patients with CDH and mixed type HA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
